Boston Scientific's Precision Plus spinal cord stimulator gains CE
13 September 2012
Boston Scientific Corporation has received European approval
for use of its Precision Plus spinal cord stimulator (SCS) System, the
world's first rechargeable SCS device, in peripheral nerve stimulation
for patients with chronic intractable pain of the trunk.
Peripheral nerve stimulation provides physicians and patients
with an additional treatment option for managing chronic intractable
pain of the trunk by stimulating peripheral nerves through a small
surgically implantable device.
"I am pleased to learn the Precision Plus SCS System has received
CE Mark approval for peripheral nerve stimulation," said Dr. David
Abejón, consultant anaesthetist at Hospital Universitario Puerta de
Hierro Majadahonda, Madrid. "Based on my clinical experience and
research with peripheral nerve stimulation therapy to date, this
technique seems to be a promising treatment option in the field of
chronic intractable pain management."
Chronic intractable pain is continuous pain has lasted more than
six months. Living in constant pain for an extended period time can
have a devastating impact to quality of life for many patients.
Without relief, or the hope for relief, many patients lose the
ability to sleep, work, and function normally.
"Chronic pain affects nearly 95 million adults throughout
Europe," said Michael Onuscheck, senior vice president and president
of Europe, Middle East and Africa at Boston Scientific. "Expanding
our neuromodulation portfolio to include peripheral nerve
stimulation with the PRECISION PLUS SCS System continues our
commitment to providing physicians and patients with multiple
treatment options for the management of this debilitating